Investment Banking
Healthcare & Life Sciences

OncoNano Announces $11.7 Million Series A Financing to Support Development of pH-Activated Compound Platform for Disease Detection and Treatment

Published on
May 17, 2018

Summary

OncoNano Medicine, Inc. today announced the closing of a $11.7 million Series A financing. The transaction was arranged by Salem Partners, who also participated as a principal investor. The Series A funding supplements a $6 million grant from the Cancer Prevention and Research Institute of Texas(CPRIT). The funding will be used to support the company’s continued development of a new class of pH-activated compounds that digitize and exploit the variability of pH in disease indications. The company is also pleased to announce the appointment of five established industry leaders to its inaugural Board of Directors.

Team Members Involved

Meet the talented individuals who brought their expertise and dedication to this project. Their collaboration, insight, and commitment to excellence were instrumental in delivering impactful results for our clients.

No team members are listed for this project.

Related News Articles

Stay updated with the latest industry news.

Related News Articles

Stay updated with the latest industry news.

Have questions? Our team is here to help

Whether you're seeking guidance on a complex transaction, exploring investment banking possibilities, or looking for wealth management strategies, our team is here to help.

Stay in touch

Provide your email to join our distribution list. By providing your email you consent to receive emails from Salem Partners Wealth Management.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.